argenx vs Takeda Pharmaceutical

argenx (ARGX), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Takeda Pharmaceutical is worth $69.3B on the stock market and argenx $59.4B: Takeda Pharmaceutical is valued at 17% more. argenx trades at 32.7 times earnings and Takeda Pharmaceutical at 310; operating margins in their latest fiscal years were 25.4% and 0.14%. Over the past year argenx's share price has moved +3.53% and Takeda Pharmaceutical's +53.4%.

Key facts

argenx market value
$59.4B
Takeda Pharmaceutical market value
$69.3B
argenx P/E
32.7
Takeda Pharmaceutical P/E
310
argenx revenue
$4.2BFY to 2025-12-31
Takeda Pharmaceutical revenue
$28.2BFY to 2026-03-31
Superinvestors holding both
0

Market values as of .

argenx vs Takeda Pharmaceutical: every measure side by side
Measure argenx Takeda Pharmaceutical
SectorHealth CareHealth Care
Country Belgium Japan
Fiscal year ends2025-12-312026-03-31
Size
Market cap$59.4Blower$69.3Bhigher
Revenue$4.2Blower$28.2Bhigher
Earnings$1.3Bhigher-$954.4Mlower
Employees1,863lower47,029higher
Total assets$8.7Blower$97.1Bhigher
Valuation
P/E32.7lower310higher
P/S14.3higher2.5lower
P/B——
Dividend yield——
Profitability
Operating margin25.4%higher0.14%lower
Balance sheet
Net assets$7.3Blower$46.5Bhigher
Total liabilities$1.4Blower$50.6Bhigher
Total debt—$30.6B
Cash on hand$3.5Blower$3.7Bhigher
Price change
Today-0.62%lower+0.46%higher
1 year+3.53%lower+53.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

argenx only (2)

Takeda Pharmaceutical only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns ARGX · Who owns TAK

Further comparisons

Learn

Questions and answers

Which is bigger, argenx or Takeda Pharmaceutical?

By market value, Takeda Pharmaceutical is the larger: $69.3B against $59.4B for argenx. By revenue in its latest fiscal year, Takeda Pharmaceutical is the larger: $28.2B against $4.2B for argenx.

Which has the higher P/E ratio?

Takeda Pharmaceutical: 310, against 32.7 for argenx. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

argenx: 25.4%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both argenx and Takeda Pharmaceutical?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold argenx and 2 hold Takeda Pharmaceutical.

Cite this page

Funkfolio, “argenx vs Takeda Pharmaceutical”, data as of 17 November 2026. https://funkfolio.com/compare/argx-vs-tak

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.